立体定向放疗用于结直肠癌肝与肺寡转移的研究进展

doi:10.3760/cma.j.cn113030-20200330-00145

摘要
图/表
参考文献(40)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

文章导读

摘要寡转移是肿瘤从局部区域病变进展到远处广泛转移过程中存在的一种中间状态,通过局部治疗有获得长期生存的可能。体部立体定向放疗(SBRT)单次剂量高、分割次数少,是一种高精准的局部消融治疗手段。结直肠癌有近一半患者会发生转移,主要转移部位为肝和肺。本文主要阐述SBRT治疗结直肠癌肝、肺寡转移灶的安全性、近期疗效及其影响因素,同时也总结了SBRT具体实施的要点。SBRT在严格的呼吸运动管理和放疗质控下是治疗结直肠癌寡转移的有效手段。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	雷俊琴
	刘文扬
	金晶

关键词 ：肿瘤/寡转移, 结直肠癌,肝转移/立体定向放射疗法, 结直肠癌,肺转移/立体定向放射疗法, 研究进展

Abstract：Oligometastasis is an intermediate status between the locally advanced andwide spread disease. Patients with oligometastasis may obtain long-term survival after local treatment. Stereotactic body radiation therapy (SBRT) can deliver radical ablative doses in a small number of fractions, which is a highly precise local ablation therapy. Approximately half of patients diagnosed with colorectal cancer (CRC) will develop metastases, with the liver and lung as the most common site of involvement. In this article, the safety, local efficacy and prognostic factors of SBRT for liver and lung oligometastases from CRC were illustrated. The highlights of SBRT implementation were also discussed. SBRT is safe and effective for oligometastases from CRC under respiratory motion management and robust quality assurance.

Key words： Neoplasm/oligometastasis Colorectal cancer, liver metastasis/stereotactic body radiation therapy Colorectal cancer, lung metastasis/Stereotactic body radiation therapy Research progress

收稿日期: 2020-03-30

ZTFLH:

基金资助:

通讯作者: 金晶,Email:jinjing@csco.org.cn

引用本文:

雷俊琴,刘文扬,金晶. 立体定向放疗用于结直肠癌肝与肺寡转移的研究进展[J]. 中华放射肿瘤学杂志, 2021, 30(12): 1316-1320.

Lei Junqin,Liu Wenyang,Jin Jing. Stereotactic body radiation therapy for liver and lung oligometastases from colorectal cancer:safety, local efficacy and prognostic factors[J]. Chinese Journal of Radiation Oncology, 2021, 30(12): 1316-1320.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.cn113030-20200330-00145 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2021/V30/I12/1316

[1] Hellman S, Weichselbaum RR. Oligometastasis[J]. J Clin Oncol, 1995, 13(1):8-10.
[2] Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer[J]. Ann Oncol, 2016, 27(8):1386-1422. DOI:10.1093/annonc/mdw235.
[3] Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease:a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation[J]. Lancet Oncol, 2020, 21(1):e18-e28. DOI:10.1016/S1470-2045(19)30718-1.
[4] Ruers T, Van Coevorden F, Punt CJ, et al. Local treatment of unresectable colorectal liver metastases:results of a randomized phase Ⅱ trial[J]. J Natl Cancer Inst, 2017, 109(9) DOI:10.1093/jnci/djx015.
[5] Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET):a randomised, phase 2, open-label trial[J]. Lancet, 2019, 393(10185):2051-2058. DOI:10.1016/S0140-6736(18)32487-5.
[6] Gomez DR, Blumenschein GR Jr, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy:a multicentre, randomised, controlled, phase 2 study[J]. Lancet Oncol, 2016, 17(12):1672-1682. DOI:10.1016/S1470-2045(16)30532-0.
[7] Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer:a phase 2 randomized clinical trial[J]. JAMA Oncol, 2018, 4(1):e173501. DOI:10.1001/jamaoncol.2017.3501.
[8] Vautravers-Dewas C, Dewas S, Bonodeau F, et al. Image-guided robotic stereotactic body radiation therapy for liver metastases:is there a dose response relationship?[J]. Int J Radiat Oncol Biol Phys, 2011, 81(3):e39-47. DOI:10.1016/j.ijrobp.2010.12.047.
[9] Scorsetti M, Arcangeli S, Tozzi A, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial[J]. Int J Radiat Oncol Biol Phys, 2013, 86(2):336-342. DOI:10.1016/j.ijrobp.2012.12.021.
[10] Berber B, Ibarra R, Snyder L, et al. Multicentre results of stereotactic body radiotherapy for secondary liver tumours[J]. HPB (Oxford), 2013, 15(11):851-857. DOI:10.1111/hpb.12044.
[11] Goodman BD, Mannina EM, Althouse SK, et al. Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases[J]. Pract Radiat Oncol, 2016, 6(2):86-95. DOI:10.1016/j.prro.2015.10.011.
[12] Ahmed KA, Caudell JJ, El-Haddad G, et al. Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2016, 95(5):1399-1404. DOI:10.1016/j.ijrobp.2016.03.050.
[13] Mahadevan A, Blanck O, Lanciano R, et al. Stereotactic body radiotherapy (SBRT) for liver metastasis-clinical outcomes from the international multi-institutional RSSearch^®patient registry[J]. Radiat Oncol, 2018, 13(1):26. DOI:10.1186/s13014-018-0969-2.
[14] Chang DT, Swaminath A, Kozak M, et al. Stereotactic body radiotherapy for colorectal liver metastases:a pooled analysis[J]. Cancer, 2011, 117(17):4060-4069. DOI:10.1002/cncr.25997.
[15] Scorsetti M, Comito T, Tozzi A, et al. Final results of a phase Ⅱ trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer[J]. J Cancer Res Clin Oncol, 2015, 141(3):543-553. DOI:10.1007/s00432-014-1833-x.
[16] Méndez-Romero A, Keskin-Cambay F, van Os RM, et al. Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy[J]. Rep Pract Oncol Radiother, 2017, 22(2):126-131. DOI:10.1016/j.rpor.2016.10.003.
[17] Joo JH, Park Jh, Kim JC, et al. Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer[J]. Int J Radiat Oncol Biol Phys, 2017, 99(4):876-883. DOI:10.1016/j.ijrobp.2017.07.030.
[18] McPartlin A, Swaminath A, Wang R, et al. Long-term outcomes of phase 1 and 2studies of SBRT for hepatic colorectal metastases[J]. Int J Radiat Oncol Biol Phys, 2017, 99(2):388-395. DOI:10.1016/j.ijrobp.2017.04.010.
[19] Petrelli F, Comito T, Barni S, et al. Stereotactic body radiotherapy for colorectal cancer liver metastases:a systematic review[J]. Radiother Oncol, 2018, 129(3):427-434. DOI:10.1016/j.radonc.2018.06.035.
[20] Miften M, Vinogradskiy Y, Moiseenko V, et al. Radiation dose-volume effects for liver SBRT[J]. Int J Radiat Oncol Biol Phys, 2021, 110(1):196-205. DOI:10.1016/j.ijrobp.2017.12.290.
[21] Franzese C, Comito T, Toska E, et al. Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy[J]. Radiother Oncol, 2019, 133:220-226. DOI:10.1016/j.radonc.2018.10.024.
[22] Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma:A systematic review and meta-analysis of observational studies[J]. Radiother Oncol, 2019, 131:135-144. DOI:10.1016/j.radonc.2018.12.005.
[23] Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017, 15(4):504-535. DOI:10.6004/jnccn.2017.0050.
[24] Filippi AR, Badellino S, Ceccarelli M, et al. Stereotactic ablative radiation therapy as first local therapy for lung oligometastases from colorectal cancer:a single-institution cohort study[J]. Int J Radiat Oncol Biol Phys, 2015, 91(3):524-529. DOI:10.1016/j.ijrobp.2014.10.046.
[25] Jung J, Song SY, Kim JH, et al. Clinical efficacy of stereotactic ablative radiotherapy for lung metastases arising from colorectal cancer[J]. Radiat Oncol, 2015, 10:238. DOI:10.1186/s13014-015-0546-x.
[26] Agolli L, Bracci S, Nicosia L, et al. Lung metastases treated with stereotactic ablative radiation therapy in oligometastatic colorectal cancer patients:outcomes and prognostic factors after long-term follow-up[J]. Clin Colorectal Cancer, 2017, 16(1):58-64. DOI:10.1016/j.clcc.2016.07.004.
[27] Mihai A, Mu Y, Armstrong J, et al. Patients with colorectal lung oligometastases (L-OMD) treated by dose adapted SABR at diagnosis of oligometastatic disease have better outcomes than patients previously treated for their metastatic disease[J]. J Radiosurg SBRT, 2017, 5(1):43-53.
[28] Jingu K, Matsuo Y, Onishi H, et al. Dose escalation improves outcome in stereotactic body radiotherapy for pulmonary oligometastases from colorectal cancer[J]. Anticancer Res, 2017, 37(5):2709-2713. DOI:10.21873/anticanres.11621.
[29] Kinj R, Bondiau PY,FrançoisE, et al. Radiosensitivity of colon and rectal lung oligometastasis treated with stereotactic ablative radiotherapy[J]. Clin Colorectal Cancer, 2017, 16(3):e211-e220. DOI:10.1016/j.clcc.2016.08.003.
[30] Sharma A, Baker S, Duijm M, et al. Prognostic factors for local control and survival for inoperable pulmonary colorectal oligometastases treated with stereotactic body radiotherapy[J]. Radiother Oncol, 2020, 144:23-29. DOI:10.1016/j.radonc.2019.10.004.
[31] Takeda A, Kunieda E, Ohashi T, et al. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer[J]. Radiother Oncol, 2011, 101(2):255-259. DOI:10.1016/j.radonc.2011.05.033.
[32] Binkley MS, Trakul N, Jacobs LR, et al. Colorectal histology is associated with an increased risk of local failure in lung metastases treated with stereotactic ablative radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2015, 92(5):1044-1052. DOI:10.1016/j.ijrobp.2015.04.004.
[33] Meyer JJ, Foster RD, Lev-Cohain N, et al. A phase I dose-escalation trial of single-fraction stereotactic radiation therapy for liver metastases[J]. Ann Surg Oncol, 2016, 23(1):218-224. DOI:10.1245/s10434-015-4579-z.
[34] Hanna GG, Murray L, Patel R, et al. UK consensus on normal tissue dose constraints for stereotactic radiotherapy[J]. Clin Oncol (R Coll Radiol), 2018, 30(1):5-14. DOI:10.1016/j.clon.2017.09.007.
[35] McGarry RC, Papiez L, Williams M, et al. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma:phase I study[J]. Int J Radiat Oncol Biol Phys, 2005, 63(4):1010-1015. DOI:10.1016/j.ijrobp.2005.03.073.
[36] Videtic GM, Paulus R, Singh AK, et al. Long-term follow-up on NRG oncology RTOG 0915(NCCTG N0927):a randomized phase 2 study comparing 2stereotactic body radiation therapy schedules for medically inoperable patients with stage Ⅰ peripheral non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2019, 103(5):1077-1084. DOI:10.1016/j.ijrobp.2018.11.051.
[37] Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer[J]. JAMA, 2010, 303(11):1070-1076. DOI:10.1001/jama.2010.261.
[38] Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase Ⅱ study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer[J]. J Clin Oncol, 2006, 24(30):4833-4839. DOI:10.1200/JCO.2006.07.5937.
[39] Bezjak A, Paulus R, Gaspar LE, et al. Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer:NRG oncology/RTOG 0813 trial[J]. J Clin Oncol, 2019, 37(15):1316-1325. DOI:10.1200/JCO.18.00622.
[40] Xiao Y, Papiez L, Paulus R, et al. Dosimetric evaluation of heterogeneity corrections for RTOG 0236:stereotactic body radiotherapy of inoperable stage Ⅰ-Ⅱ non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2009, 73(4):1235-1242. DOI:10.1016/j.ijrobp.2008.11.019.